In the present invention, it was discovered that when vascular endothelial cells are co-cultured with mesenchymal stem cells, an improvement is brought about in the niche activity of mesenchymal stem cells and the self-renewal of hematopoietic or neural stem cells and particularly that the niche activity and the self-renewal of hematopoietic or neural stem cells can easily be controlled by regulating the stimulus (cytokines, etc.) of vascular endothelial cells to the mesenchymal stem cells. Therefore, the present invention can not only improve the self-renewal of stem cells, but also easily control it as needed, and thus is expected to expand the usefulness of mesenchymal stem cell-based cell therapy.

The present disclosure relates to a non-alcoholic fatty liver artificial tissue model. As compared to a conventional technology by which tissues are cultured only in Matrigel including a device composed of a decellularized liver tissue-derived extracellular matrix and a plurality of microchannels or a decellularized liver tissue-derived extracellular matrix, the present disclosure enables better mimicking of an actual non-alcoholic fatty liver disease due to the presence of Kupffer cells and hepatic stellate cells. Also, according to the present disclosure, the growth of liver organoids can be improved and fat accumulation and inflammation in the liver organoids can be caused to occur well through free fatty acid treatment, and the phenotypes of non-alcoholic fatty liver can be better expressed.

The present disclosure relates to methods for modulating the level of proteins in a subject or in target cells by priming red blood cells with various agents or conditions that modulate the levels of proteins associated with red blood cells and administering the primed red blood cells to a subject. The disclosed methods represent a novel use of red blood cells primed to express a number of proteins, as cell therapies for numerous diseases or disorders.

Tissue engineered constructs and methods for fabricating the disclosed constructs are provided. Some of the disclosed tissue engineered constructs are designed to fill a void in the body due to surgical resection, for example from mastectomy or lumpectomy, wounds and the like. Some disclosed constructs comprise one or more projections designed to mimic the appearance of a structural feature when implanted into a host.

This disclosure describes an adaptive NK cell, an isolated population of adaptive Natural Killer (NK) cells, a composition including an adaptive NK cell, and methods for producing, preparing, and using an adaptive NK cell or an isolated population or composition including an adaptive NK cell. The adaptive NK cells may be used to treat a viral infection or a tumor.

The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein.

##STR00001##

The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

A method for modifying gene expression of diseased cells in a patient including preparing an extract of diseased cells, forming a plurality of conditioned stem cells by treating a plurality of normal stem cells with a solution of the extract of the diseased cells with a volume ratio between 10.sup.?15 volume/volume (v/v) and 10.sup.?3 v/v (volume of the extract of the diseased cells/volume of a culture medium), forming a conditioned stem cell-derived extract, and forming a plurality of healthy cells by treating the diseased cells with the conditioned stem cell-derived extract.

This disclosure describes an adaptive NK cell, an isolated population of adaptive Natural Killer (NK) cells, a composition including an adaptive NK cell, and methods for producing, preparing, and using an adaptive NK cell or an isolated population or composition including an adaptive NK cell. The adaptive NK cells may be used to treat a viral infection or a tumor.

A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.